Merit Medical Systems, Inc. (NASDAQ:MMSI) Position Lowered by F M Investments LLC

F M Investments LLC lowered its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 14.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 125,043 shares of the medical instruments supplier’s stock after selling 20,971 shares during the quarter. F M Investments LLC owned about 0.22% of Merit Medical Systems worth $12,358,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of MMSI. Opal Wealth Advisors LLC bought a new position in Merit Medical Systems during the second quarter worth $29,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Merit Medical Systems in the 1st quarter valued at about $44,000. USA Financial Formulas bought a new stake in shares of Merit Medical Systems during the 3rd quarter valued at about $59,000. Headlands Technologies LLC acquired a new stake in Merit Medical Systems during the first quarter worth about $50,000. Finally, GAMMA Investing LLC grew its holdings in shares of Merit Medical Systems by 142.3% during the second quarter. GAMMA Investing LLC now owns 831 shares of the medical instruments supplier’s stock valued at $71,000 after purchasing an additional 488 shares during the last quarter. Institutional investors own 99.66% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on MMSI shares. StockNews.com upgraded Merit Medical Systems from a “hold” rating to a “buy” rating in a research report on Saturday, October 26th. Wells Fargo & Company upped their price target on shares of Merit Medical Systems from $85.00 to $103.00 and gave the stock an “equal weight” rating in a research report on Monday, September 16th. Needham & Company LLC reiterated a “buy” rating and issued a $109.00 price objective on shares of Merit Medical Systems in a research report on Thursday. Bank of America upped their target price on shares of Merit Medical Systems from $92.00 to $103.00 and gave the stock a “neutral” rating in a research report on Monday, September 16th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $114.00 price target on shares of Merit Medical Systems in a report on Thursday. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Merit Medical Systems has a consensus rating of “Moderate Buy” and an average price target of $103.36.

Merit Medical Systems Price Performance

NASDAQ MMSI traded up $0.14 on Friday, reaching $98.80. 392,724 shares of the stock traded hands, compared to its average volume of 437,975. Merit Medical Systems, Inc. has a 12 month low of $65.46 and a 12 month high of $101.60. The company has a quick ratio of 4.64, a current ratio of 6.24 and a debt-to-equity ratio of 0.62. The firm’s fifty day simple moving average is $96.60 and its 200 day simple moving average is $87.89. The company has a market cap of $5.75 billion, a price-to-earnings ratio of 48.43, a P/E/G ratio of 2.39 and a beta of 0.87.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 EPS for the quarter, beating the consensus estimate of $0.80 by $0.06. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.86%. The business had revenue of $339.85 million during the quarter, compared to the consensus estimate of $334.60 million. During the same quarter in the prior year, the firm earned $0.75 EPS. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. As a group, research analysts predict that Merit Medical Systems, Inc. will post 3.3 EPS for the current fiscal year.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.